

(12) International Application Status Report

Received at International Bureau: 25 August 2018 (25.08.2018)

Information valid as of: 19 February 2019 (19.02.2019)

Report generated on: 17 January 2020 (17.01.2020)

(10) Publication number:

WO2019/032910

(43) Publication date:

14 February 2019 (14.02.2019)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/US2018/046130

(22) Filing Date:

09 August 2018 (09.08.2018)

(25) Filing language:

English (EN)

(31) Priority number(s):

62/543,215 (US)

(31) Priority date(s):

09 August 2017 (09.08.2017)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

62/594,399 (US)

04 December 2017 (04.12.2017)

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61K 31/4155 (2006.01); **A61K 9/08** (2006.01); **A61P 29/00** (2006.01)

(71) Applicant(s):

PIEDMONT ANIMAL HEALTH LLC [US/US]; 204 Muirs Chapel Road, Suite 200 Greensboro, NC 27410 (US) *(for all designated states)*

(72) Inventor(s):

HEPLER, Douglas; c/o Piedmont Animal Health LLC 204 Muirs Chapel Road, Suite 200 Greensboro, NC 27410 (US)
DEMPSEY, Gail, L.; c/o Piedmont Animal Health LLC 204 Muirs Chapel Road, Suite 200 Greensboro, NC 27410 (US)
JOHNSON, Roland; c/o Piedmont Animal Health LLC 204 Muirs Chapel Road, Suite 200 Greensboro, NC 27410 (US)
KELLY, Michael; c/o Piedmont Animal Health LLC 204 Muirs Chapel Road, Suite 200 Greensboro, NC 27410 (US)
DANIEL, Michael; c/o Piedmont Animal Health LLC 204 Muirs Chapel Road, Suite 200 Greensboro, NC 27410 (US)
PAULSEN, Neil, E.; c/o Piedmont Animal Health LLC 204 Muirs Chapel Road, Suite 200 Greensboro, NC 27410 (US)
CLAYTON, Bert; c/o Piedmont Animal Health LLC 204 Muirs Chapel Road, Suite 200 Greensboro, NC 27410 (US)

(74) Agent(s):

HIERHOLZER, Matthew, J.; DLA Piper LLP (US) 4365 Executive Drive, Suite 1100 San Diego, CA 92121-2133 (US)

(54) Title (EN): THERAPEUTIC FORMULATIONS AND USES THEREOF

(54) Title (FR): FORMULATIONS THÉRAPEUTIQUES ET LEURS UTILISATIONS

(57) Abstract:

(EN): Provided herein are pharmaceutically acceptable compositions containing a selective cyclooxygenase-2 (COX-2) inhibitor (coxib) and optionally buprenorphine. In particular, compositions containing a coxib formulated for oral, topical or subcutaneous administration to treat pain or inflammation are described.

(FR): L'invention concerne des compositions pharmaceutiquement acceptables contenant un inhibiteur sélectif de la cyclo-oxygénase -2 (COX -2) et éventuellement de la buprénorphine. En particulier, l'invention concerne des compositions contenant un coxib formulé pour une administration orale, topique ou sous-cutanée pour traiter la douleur ou l'inflammation.

International search report:

Received at International Bureau: 06 December 2018 (06.12.2018) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:

Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate

Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii))